



- (51) International Patent Classification:
C40B 30/02 (2006.01) *C40B 30/10* (2006.01)
C40B 30/08 (2006.01)
- (21) International Application Number:
PCT/US2015/028385
- (22) International Filing Date:
30 April 2015 (30.04.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/986,480 30 April 2014 (30.04.2014) US
- (71) Applicants: NATIONAL TAIWAN UNIVERSITY; No. 1, Sec. 4, Roosevelt Rd., Taipei, 10617 (TW). NATIONAL CHIAO TUNG UNIVERSITY; 1001 University Road, Hsinchu, 300 (TW). NATIONAL HEALTH RESEARCH INSTITUTES; 35, Keyan Road, Zhunan Town, Miaoli County, 350 (TW).
- (72) Inventor; and
(71) Applicant : TSENG, Yufeng, Jane [US/US]; 70 Masters Mill Court, Stafford, VA 22556-8616 (US).
- (72) Inventors: LIU, Yu-Li; 35, Keyan Road, Zhunan Town, Miaoli County, 350 (TW). SUN, Chung-Ming; 1001 University Road, Hsinchu, 300 (TW). HWU, Hai-Gwo; No. 1, Sec. 4, Roosevelt Rd., Taipei, 10617 (TW). LIU, Chih-Min; No. 1, Sec. 4, Roosevelt Rd., Taipei, 10617 (TW).
- (74) Agents: BIRO, Michael, G. et al.; Lathrop & Gage LLP, 28 State Street, Boston, MA 02109 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: USE OF KNOWN COMPOUNDS AS D-AMINO ACID OXIDASE INHIBITORS




Fig. 1a

(57) Abstract: The invention utilizes virtual screening strategy to seek for current market drugs as anti-schizophrenia therapy—drug repurposing. Drug repurposing strategy finds new uses other than the original medical indications of existing drugs. Finding new indications for such drugs will benefit patients who are in needs for a potential new therapy sooner since known drugs are usually with acceptable safety and pharmacokinetic profiles. In this study, repurposing marketed drugs for DAAO inhibitor as new schizophrenia therapy was performed with virtual screening on marketed drugs and its metabolites. The identified and available drugs and compounds were further confirmed with in vitro DAAO enzymatic inhibitory assay.



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE,

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*